A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. - Wikidata - awgldk - TriplyDB

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

http://www.wikidata.org/entity/Q43033369

about

PEGylation of Interferon-β-1a Hepatitis C: a review for primary care physicians Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Structure-function analysis of the 3' stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication 3' nontranslated RNA signals required for replication of hepatitis C virus RNA Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Optimal clinical trial designs for immune-based therapies in persistent viral infections Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications Interference of hepatitis C virus RNA replication by short interfering RNAs Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins New developments in the treatment of hepatitis C Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin Drug Pricing Evolution in Hepatitis C Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients Promising candidates for the treatment of chronic hepatitis C.Therapeutic alpha-interferons protein: structure, production, and biosimilar.Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations.Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.Treatment of hepatitis C. The 2002 French consensus.Chronic hepatitis C treatment patterns in African American patients: an update.Hematologic disorders associated with hepatitis C virus infection and their management.Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Triple antiviral therapy in HCV positive patients who failed prior combination therapy Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?PCBP2 enhances the antiviral activity of IFN-α against HCV by stabilizing the mRNA of STAT1 and STAT2.Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

P2860

Q22241420-5FE2F35D-D2B7-4BE7-86B1-95647D9872D0 Q22306040-E7EF2513-F82E-4FDF-8AAF-49EC6EC966C8 Q24201588-0E4689AD-BB41-4C80-B600-2A38DE75F3DD Q24540195-ED8743AC-F464-4891-B968-0838CB26DD42 Q24550606-4CB50AAE-D45B-4275-966F-4EE421F2232E Q24596340-5A5C5E63-CB6E-47D1-AA75-D457A64291F3 Q24644729-87F91324-DE69-4A95-B88F-F8807BC29977 Q24799820-7BA1D3DF-34B1-495D-81DE-7446471D1844 Q26777408-58BFC265-E2CA-45A5-85F0-C9A32E753F11 Q27473349-DCA80959-276C-47A5-A6FC-540E0976794A Q27473398-DB6AE2CA-744D-485A-9A19-7818C17AE29D Q27473469-E547A693-ABEB-4C81-AB50-01317E44F380 Q27477964-0828A9A6-8C9D-45CE-94CA-21B31F277DE3 Q27480999-8B21F29E-046E-4C0B-9E95-FFA00B42F22E Q27481007-28A3F892-10A2-404E-9751-311B57F9F8C4 Q27485351-5A4CDCA4-FE7E-4E39-B1A2-9C195244BF7A Q27486648-29AE1674-8DAA-4A35-B92A-BFB77E826F60 Q28550311-7CCEA32E-D48E-4081-BF28-336853E04CC9 Q28740552-E402561A-15C5-40D6-B2CC-9F2159644DEF Q30333233-0B5B8E3C-A0E6-4A1C-A4D6-ABA19E63C9ED Q30361968-3072C351-D15E-413B-B02A-27B825F46DB1 Q30733177-9351A878-D1C4-479C-857C-D73D7252077A Q30892564-C215157C-B153-4CD9-82B5-0406C4523811 Q33195269-340CBA0B-90F8-41E4-8764-13F9029593D5 Q33212476-F801108B-5D7F-414C-AB1E-AAC66273221F Q33349378-158FACC9-D301-49A2-9B0D-681C2CC896CA Q33365961-81A4627F-3B8C-43E2-8A99-7C260CB74D43 Q33365990-454B716B-0B44-45F5-856C-2EDE1C257779 Q33370971-94672BE5-B958-4037-A31C-A8841F9EF9FD Q33557770-8A3614C9-C2BB-414B-8DF8-771D3841A05F Q33621649-FBC3769E-F5E0-4EEC-B905-4BFBBA513DA5 Q33788496-2E67E95D-68E7-4063-8543-4E87BA92DFAD Q33816657-0675D349-3FD6-414A-BEBA-937BE8AEE986 Q33869358-4B9AC133-6872-4E3B-943D-F32B1FE296FB Q33869578-CF789D00-C093-46C9-8F86-7ED49958A89B Q33906899-13691C72-5A8B-4C2A-A3A4-A03E98AF4CF6 Q34003800-CAD37A92-F6BD-4190-9AB0-638058EDDD04 Q34055577-7E9882BA-1A03-4269-B162-673B7168B507 Q34087387-7B21EB74-1365-4ED6-A64A-EB53B9A2AE67 Q34225751-2BF1598F-053A-4E1D-9595-2CB67618754B

P2860

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

http://www.wikidata.org/entity/Q43033369

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@en

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@nl

type

label

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@en

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@nl

prefLabel

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@en

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@nl

P1433

Q43033369-39884A32-DE2B-4FE3-A7FE-C418FB6C781B

P1476

Q43033369-19B4A259-B693-4890-B13D-23693800BFD1

P2093

Q43033369-1DF75FC7-E3FD-4774-86F3-FE691F57C60C

Q43033369-1F7BCE1A-F1AF-4856-9B2D-1DAED22837EC

Q43033369-68C799D8-BAC6-443F-B642-80B434DC0A47

Q43033369-B4CADE44-696E-4AB3-9C32-1C793DA08C3F

Q43033369-B5A81955-CA03-48D7-9F07-2EB5F6DE1A05

Q43033369-BEBDD0C5-8870-452D-924E-12D36A718CFE

Q43033369-DEF18AC2-465A-469C-989A-8865274377C5

Q43033369-EA9D42C3-BFFE-4A66-A8D4-B7E99CB755F4

Q43033369-ECDFF777-BAD4-47B8-8DB4-24C58A30E4D8

Q43033369-EDA1BBDE-4102-42A2-AC43-7B2941EECBDA

P304

Q43033369-318076AC-14FF-4AE2-85E2-64FE4F56CA46

P31

Q43033369-FEEEC486-1F66-47E4-A393-B22A7A0E4A7D

P356

Q43033369-2C1C4FDE-BFDB-4C4A-9B8C-F046D8335B35

P407

Q43033369-26B9C369-D93C-4AA9-99D9-CB6A56054DD4

P433

Q43033369-9E5905E3-2E43-4593-B520-5C6BF93D8EBC

P478

Q43033369-73B25A6C-266F-45C2-B01B-5E53DAFA0C53

P577

Q43033369-72C29100-979C-463B-8D45-03B3F5975DDC

P5875

Q43033369-9E0CC7BC-B563-470C-805B-25BC6CCC5A36

P698

Q43033369-788A95E8-619A-4520-9F48-0AD15C653419

P356

JHEP.2001.26371

P1433

P1476

A randomized, double-blind tri ...... tment for chronic hepatitis C.

@en

P2093

C Trepo

http://www.w3.org/2001/XMLSchema#string

E R Schiff

http://www.w3.org/2001/XMLSchema#string

Hepatitis Interventional Therapy Group

http://www.w3.org/2001/XMLSchema#string

J C Hoefs

http://www.w3.org/2001/XMLSchema#string

J K Albrecht

http://www.w3.org/2001/XMLSchema#string

K L Lindsay

http://www.w3.org/2001/XMLSchema#string

M L Shiffman

http://www.w3.org/2001/XMLSchema#string

M Laughlin

http://www.w3.org/2001/XMLSchema#string

R Yao

http://www.w3.org/2001/XMLSchema#string

S C Gordon

http://www.w3.org/2001/XMLSchema#string

P304

395-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2001.26371

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227609110

http://www.w3.org/2001/XMLSchema#string

P698

11481625

http://www.w3.org/2001/XMLSchema#string